Background: Early detection of individuals at high risk for chronic kidney disease (CKD) may aid prevention. Urinary levels of trefoil factor 3 (TFF3) are associated with acute kidney injury in animal models, but the association of TFF3 levels with incident CKD in humans is unknown. Methods: We conducted a case-control study nested within the Atherosclerosis Risk in Communities (ARIC) Study and the ARIC Carotid MRI Study to determine whether urinary TFF3 levels predict incident CKD over 8.6 years of follow-up. A total of 143 participants with incident CKD (eGFR decreasing by ≧25% to <60 ml/min/1.73 m2) were matched on age, sex and race to 143 non-cases. Results: Higher TFF3 levels at baseline were strongly associated with Black race, diabetes (both p = 0.002), and antihypertensive medication use (p = 0.02). Compared to participants with TFF3 levels in the lowest quartile, the odds ratio (OR) of incident CKD was 1.84 (95% confidence interval (CI): 0.80, 4.22) for individuals with TFF3 levels in the second quartile, 2.43 (95% CI: 1.06, 5.53) for the third quartile, and 2.77 (95% CI: 1.22, 6.28) for the fourth quartile (p trend = 0.02). Adjustment for covariates, including urinary albumin: creatinine ratio, did not markedly change the associations. Twofold higher TFF3 levels were strongly associated with incident CKD after adjustment for CKD risk factors (adjusted OR = 1.35; 95% CI: 1.11, 1.64). Conclusions: Higher urinary TFF3 levels may indicate ongoing repair of damage in the kidney. Additional studies are needed to confirm whether TFF3 can be useful as a marker of increased risk for CKD.

Keywords:
Kidney disease, Tubulointerstitual disease, Biomarkers
1.
Astor BC, Hallan SI, Miller ER III, et al: Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 2008;167:1226–1234.
2.
Shlipak MG, Sarnak MJ, Katz R, et al: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352:2049–2060.
3.
Bash LD, Astor BC, Coresh J: Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2010;55:31–41.
4.
Fliser D, Kronenberg F, Kielstein JT, et al: Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005;16:2456–2461.
5.
Fliser D, Kollerits B, Neyer U, et al: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007;18:2600–2608.
6.
Spanaus KS, Kronenberg F, Ritz E, et al: B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study. Clin Chem 2007;53:1264–1272.
7.
Kronenberg F: Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol 2009;5:677–689.
8.
Bleyer AJ, Shemanski LR, Burke GL, et al: Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population. Kidney Int 2000;57:2072–2079.
9.
Fox CS, Larson MG, Leip EP, et al: Predictors of new-onset kidney disease in a community-based population. JAMA 2004;291:844–850.
10.
Muntner P, Coresh J, Smith JC, et al: Plasma lipids and risk of developing renal dysfunction: the Atherosclerosis Risk in Communities Study. Kidney Int 2000;58:293–301.
11.
James MT, Hemmelgarn BR, Tonelli M: Early recognition and prevention of chronic kidney disease. Lancet 2010;375:1296–1309.
12.
Wright JT Jr, Bakris G, Greene T, et al: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421–2431.
13.
Coons SJ: The FDA’s critical path initiative: a brief introduction. Clin Ther 2009;31:2572–2573.
14.
Podolsky DK, Lynch-Devaney K, Stow JL, et al: Identification of human intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for apical secretion. J Biol Chem 1993;268:12230.
15.
Taupin D, Podolsky DK: Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol 2003;4:721–732.
16.
ARIC Investigators: The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989;129:687–702.
17.
Wasserman BA, Astor BC, Sharrett AR, et al: MRI measurements of carotid plaque in the Atherosclerosis Risk in Communities (ARIC) Study: methods, reliability and descriptive statistics. J Magn Reson Imaging 2010;31:406–415.
18.
Bash LD, Coresh J, Kottgen A, et al: Defining incident chronic kidney disease in the research setting: The ARIC Study. Am J Epidemiol 2009;170:414–424.
19.
Coresh J, Astor BC, McQuillan G, et al: Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002;39:920–929.
20.
Stevens LA, Coresh J, Feldman HI, et al: Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol 2007;18:2749–2757.
21.
Papp AC, Hatzakis H, Bracey A, et al: ARIC hemostasis study. I. Development of a blood collection and processing system suitable for multicenter hemostatic studies. Thromb Haemost 1989;61:15–19.
22.
Hoffmann W: Trefoil factor family (TFF) peptides and chemokine receptors: a promising relationship. J Med Chem 2009;52:6505–6510.
23.
Hoffmann W: TFF (trefoil factor family) peptides; in Kastin AJ (ed): Handbook of Biologically Active Peptides. San Diego, Elsevier, 2006, pp 1147–1154.
24.
Hoffmann W, Jagla W: Cell type specific expression of secretory TFF peptides: colocalization with mucins and synthesis in the brain. Int Rev Cytol 2002;213:147–181.
25.
Wong WM, Poulsom R, Wright NA: Trefoil peptides. Gut 1999;44:890–895.
26.
Rinnert M, Hinz M, Buhtz P, et al: Synthesis and localization of trefoil factor family (TFF) peptides in the human urinary tract and TFF2 excretion into the urine. Cell Tissue Res 2010;339:639–647.
27.
Hoffmann W: Trefoil factors TFF (trefoil factor family) peptide-triggered signals promoting mucosal restitution. Cell Mol Life Sci 2005;62:2932–2938.
28.
Pawar S, Kartha S, Toback FG: Differential gene expression in migrating renal epithelial cells after wounding. J Cell Physiol 1995;165:556–565.
29.
Bonventre JV: Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol 2003;14 (suppl 1):S55–S61.
30.
Romih R, Koprivec D, Martincic DS, et al: Restoration of the rat urothelium after cyclophosphamide treatment. Cell Biol Int 2001;25:531–537.
31.
Veranic P, Romih R, Jezernik K: What determines differentiation of urothelial umbrella cells? Eur J Cell Biol 2004;83:27–34.
32.
Hoffmann W: Regeneration of the gastric mucosa and its glands from stem cells. Curr Med Chem 2008;15:3133–3144.
33.
Kouznetsova I, Peitz U, Vieth M, et al: A gradient of TFF3 (trefoil factor family 3) peptide synthesis within the normal human gastric mucosa. Cell Tissue Res 2004;316:155–165.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.